Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
2.
Eur J Surg Oncol ; 42(9): 1268-77, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26947960

RESUMO

INTRODUCTION: We evaluated the impacts of a series of novel histopathological factors on clinical-surgical outcomes and survival of patients who underwent surgery for colorectal cancer liver metastasis, with and without neoadjuvant chemotherapy. MATERIALS AND METHODS: A prospective database including 150 consecutive patients who underwent 183 hepatic resections for metastatic colorectal cancer was evaluated. Among them, 74 (49.3%) received neoadjuvant chemotherapy before surgery. The histopathological factors studied were: a) microsatellitosis, b) type and pattern of tumour growth, c) nuclear grade and the number of mitoses/mm(2), d) perilesional pseudocapsule, e) intratumoural fibrosis, f) lesion cellularity, g) hypoxic-angiogenic perilesional growth pattern, and h) the tumour normal interface. RESULTS: Three or more metastatic lesions, R1 resection margins, and <50% tumour necrosis were prognostic factors for a worse OS, but only the former was confirmed to be an independent prognostic factor in the multivariate analysis. Furthermore, tumour fibrosis <40% and cellularity >10% were predictive of a worse neoadjuvant therapy response, but these findings were not confirmed in the multivariate analysis. Finally, tumour necrosis <50%, cellularity >10%, and TNI >0.5 mm were prognostic factors for a worse DFS and AS in the univariate but not in the multivariate analysis. CONCLUSIONS: Several factors seem to influence the outcomes of surgery for colorectal cancer liver metastasis, especially the number of the lesions, the margins of resection, the percentage of necrosis and fibrosis, as well as the cellularity and the TNI.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma/patologia , Neoplasias Colorretais/patologia , Neoplasias Hepáticas/patologia , Fígado/patologia , Anticorpos Monoclonais/administração & dosagem , Bevacizumab/administração & dosagem , Capecitabina , Carcinoma/secundário , Carcinoma/terapia , Cetuximab/administração & dosagem , Bases de Dados Factuais , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapêutico , Fibrose , Fluoruracila/análogos & derivados , Fluoruracila/uso terapêutico , Hepatectomia , Humanos , Leucovorina/uso terapêutico , Fígado/cirurgia , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Metastasectomia , Índice Mitótico , Análise Multivariada , Necrose , Terapia Neoadjuvante , Gradação de Tumores , Compostos Organoplatínicos/uso terapêutico , Oxaloacetatos , Panitumumabe , Prognóstico , Estudos Retrospectivos , Carga Tumoral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA